Thurston Springer Miller Herd & Titak Inc. Makes New $153,000 Investment in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 9,407 shares of the company’s stock, valued at approximately $153,000.

A number of other hedge funds have also recently made changes to their positions in TEVA. Clal Insurance Enterprises Holdings Ltd lifted its stake in shares of Teva Pharmaceutical Industries by 7.1% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 32,804,131 shares of the company’s stock worth $342,788,000 after purchasing an additional 2,188,212 shares during the last quarter. Meitav Investment House Ltd. lifted its stake in shares of Teva Pharmaceutical Industries by 82.8% during the 4th quarter. Meitav Investment House Ltd. now owns 4,305,674 shares of the company’s stock worth $44,914,000 after purchasing an additional 1,950,500 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. lifted its stake in shares of Teva Pharmaceutical Industries by 6.9% during the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 28,919,540 shares of the company’s stock worth $301,920,000 after purchasing an additional 1,860,000 shares during the last quarter. Maple Rock Capital Partners Inc. lifted its stake in shares of Teva Pharmaceutical Industries by 68.3% during the 1st quarter. Maple Rock Capital Partners Inc. now owns 4,363,401 shares of the company’s stock worth $61,568,000 after purchasing an additional 1,770,000 shares during the last quarter. Finally, Glenview Capital Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth $16,752,000. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Price Performance

TEVA traded up $0.23 during trading on Tuesday, hitting $16.91. The company’s stock had a trading volume of 10,189,324 shares, compared to its average volume of 10,453,374. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.52. Teva Pharmaceutical Industries Limited has a twelve month low of $8.06 and a twelve month high of $18.02. The business’s fifty day simple moving average is $16.79 and its 200 day simple moving average is $14.84. The firm has a market capitalization of $19.15 billion, a price-to-earnings ratio of -41.23, a P/E/G ratio of 1.49 and a beta of 0.90.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, May 8th. The company reported $0.46 earnings per share for the quarter, missing the consensus estimate of $0.49 by ($0.03). The firm had revenue of $3.82 billion during the quarter, compared to analysts’ expectations of $3.70 billion. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. On average, equities research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.35 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Piper Sandler reissued an “overweight” rating and issued a $20.00 price objective (up from $19.00) on shares of Teva Pharmaceutical Industries in a report on Monday, May 13th. Bank of America increased their price objective on Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, May 30th. Jefferies Financial Group raised their target price on Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Argus raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a report on Wednesday, July 10th. Finally, UBS Group raised their target price on Teva Pharmaceutical Industries from $22.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, July 10th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $18.67.

Insider Activity

In other news, insider Eric A. Hughes sold 24,537 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $17.25, for a total value of $423,263.25. Following the transaction, the insider now owns 45,060 shares in the company, valued at $777,285. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, insider Vikki L. Conway sold 15,219 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $16.74, for a total transaction of $254,766.06. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Eric A. Hughes sold 24,537 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $17.25, for a total value of $423,263.25. Following the transaction, the insider now owns 45,060 shares in the company, valued at approximately $777,285. The disclosure for this sale can be found here. Insiders have sold a total of 574,256 shares of company stock worth $9,776,999 over the last quarter. 0.55% of the stock is currently owned by corporate insiders.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.